Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

PURPOSE: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Talamonti, Marina, Russo, Filomena, Malara, Giovanna, Hansel, Katharina, Papini, Manuela, Cattaneo, Angelo, Parodi, Aurora, Chiricozzi, Andrea, Malagoli, Piergiorgio, Bardazzi, Federico, Brazzelli, Valeria, Dapavo, Paolo, Gisondi, Paolo, Zane, Cristina, Potenza, Concetta, Cantoresi, Franca, Fargnoli, Maria Concetta, Trevisini, Sara, Brianti, Pina, Pescitelli, Leonardo, Gigante, Giovanni, Bartezaghi, Marta, Caputo, Luisa, Aloisi, Elisabetta, Costanzo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075320/
https://www.ncbi.nlm.nih.gov/pubmed/37033782
http://dx.doi.org/10.2147/CCID.S400520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075320/
https://www.ncbi.nlm.nih.gov/pubmed/37033782
http://dx.doi.org/10.2147/CCID.S400520

Ejemplares similares